Tirzepatide reduces pulmonary embolism risk by 78.5% and DVT by 69.7% in T2DM/obesity.
Background
Venous thromboembolism (VTE), encompassing pulmonary embolism (PE) and deep vein thrombosis (DVT), is a major cause of morbidity and mortality, particularly in patients with obesity and type 2 diabetes (T2DM). Current standard-of-care often focuses on anticoagulation or lifestyle changes, but the impact of novel metabolic therapies on VTE risk is not fully characterized. Tirzepatide, a dual GIP and GLP-1 receptor agonist, improves metabolic and cardiovascular risk factors, but its real-world association with VTE has been unclear. This study addresses that gap.
Study Design
A population-based retrospective cohort study used the TriNetX US Collaborative Network. Adults with type 2 diabetes and overweight or obesity who initiated tirzepatide were propensity score matched to patients receiving lifestyle intervention alone, without weight-loss medications. The primary outcomes were incident pulmonary embolism, deep vein thrombosis, and superficial vein thrombosis occurring between 30 days and 12 months after index. A 90-day landmark sensitivity analysis and an active comparator analysis comparing tirzepatide with semaglutide were also performed.
Results
After propensity score matching, 235,200 patients were included (117,600 per cohort). Tirzepatide use was associated with a significantly lower 12-month risk of pulmonary embolism compared to lifestyle intervention alone (RR, 0.215; 95% CI, 0.185-0.250; HR, 0.258; 95% CI, 0.222-0.299; log-rank P < 0.001).
Similar significant reductions were observed for deep vein thrombosis (RR, 0.303; 95% CI, 0.270-0.340; HR, 0.361; 95% CI, 0.322-0.406; log-rank
P < 0.001). No statistically significant difference was found for superficial vein thrombosis (RR, 0.716; 95% CI, 0.484-1.060; HR, 0.868; 95% CI, 0.586-1.286; log-rankP = 0.480). Findings for PE and DVT remained significant in the 90-day landmark analysis. In the semaglutide comparator analysis, tirzepatide was associated with a significantly lower risk of deep vein thrombosis.
Key Findings
- Tirzepatide reduced 12-month pulmonary embolism risk by 78.5% (RR, 0.215) vs. lifestyle alone.
- Tirzepatide reduced 12-month deep vein thrombosis risk by 69.7% (RR, 0.303) vs. lifestyle alone.
- No significant difference in superficial vein thrombosis risk was observed (RR, 0.716;
P = 0.480). - PE and DVT reductions remained significant in a 90-day landmark analysis.
- Tirzepatide showed lower DVT risk compared to semaglutide in an active comparator analysis.
Why It Matters
Tirzepatide offers a significant protective effect against serious venous thromboembolism events in patients with type 2 diabetes and obesity. This finding suggests that beyond its established metabolic and cardiovascular benefits, tirzepatide could play a crucial role in reducing the risk of PE and DVT, which are major causes of morbidity and mortality. For clinicians, this adds another compelling reason to consider tirzepatide in at-risk populations. For individuals using tirzepatide, this provides additional reassurance regarding its broader health benefits. This real-world data supports its use as a multi-faceted therapeutic option.
tirzepatide
type-2-diabetes
obesity
pulmonary-embolism
deep-vein-thrombosis
venous-thromboembolism